Skip to content
Screener

SELLAS Life Sciences Group, Inc. SLS Total Liabilities & Equity

Total Liabilities & Equity at other companies

Pfizer logo
PfizerPFE
$207.62B-0.2%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$472.67M-26.2%
AbbVie logo
AbbVieABBV
$136.46B+0.2%
Immunome logo
ImmunomeIMNM
$619.79M+80.9%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$924M-14.0%
CTO
Citius Oncology, Inc.CTOR
$100.7M+10.1%

Other financials

Income statement

See full
Revenue-
Gross profit-
Operating income-$9.3M-52.6%
Net income-$8.4M-44.6%
EPS (diluted)-$0.05+28.6%

Balance sheet

See full
Cash & equivalents$107.1M+277%
Total debt$871.0K+0.1%
Total equity$107.4M+287%
Total assets$114.2M+227%

Cash flow

See full
Operating cash flow-$8.8M+2.5%

Valuation

See full
Market cap$2.3B+1,350%
Enterprise value$2.19B+1,537%

Profitability

See full
Gross margin90%-7.4pp
Operating margin-4,195%-4,591pp
Net margin-4,130.1%-4,444pp
FCF margin-300.5%

Returns & leverage

See full
Return on equity-43.6%-17.9pp
Debt / equity0.0×
Current ratio17.2×+12.6×

Where this comes from

Reported directly by SELLAS Life Sciences Group, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: SELLAS Life Sciences Group, Inc.’s 10-Q, filed May 12, 2026.

Filed
May 12, 2026, 4:01 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001390478-26-000008
Line itemMarch 31, 2026December 31, 2025
Total liabilities6,7657,474
Commitments and contingencies (Note 5)
Stockholders’ equity:
Common stock, $0.0001 par value; 350,000,000 shares authorized, 181,332,574 and 153,103,459 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively1815
Additional paid-in capital390,789345,844
Accumulated deficit(283,395)(274,988)
Total stockholders’ equity107,41270,871
Total liabilities and stockholders’ equity$114,177$78,345

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is SELLAS Life Sciences Group, Inc.'s total liabilities & equity?
SELLAS Life Sciences Group, Inc. (SLS) reported total liabilities & equity of $114.18M in Q1 2026.
How has SELLAS Life Sciences Group, Inc.'s total liabilities & equity changed year-over-year?
SELLAS Life Sciences Group, Inc.'s total liabilities & equity increased by 226.6% year-over-year, from $34.96M to $114.18M.
What is the long-term trend for SELLAS Life Sciences Group, Inc.'s total liabilities & equity?
Over 5 years (2020 to 2025), SELLAS Life Sciences Group, Inc.'s total liabilities & equity has grown at a 11.2% compound annual growth rate (CAGR), from $46.05M to $78.35M.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about SELLAS Life Sciences Group, Inc.'s total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude